Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CCR7 antibody-drug conjugate - Novartis Pharmaceuticals, JBH 492, JBH492 |
Target |
Mechanism CCR7 inhibitors(C-C motif chemokine receptor 7 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC38H54ClN3O10S |
InChIKeyJFCFGYGEYRIEBE-UHFFFAOYSA-N |
CAS Registry796073-69-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 1 | JP | 07 Sep 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | FI | 07 Sep 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | DE | 07 Sep 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | IL | 07 Sep 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | SG | 07 Sep 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | KR | 07 Sep 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | ES | 07 Sep 2020 | |
Non-Hodgkin Lymphoma | Phase 1 | JP | 07 Sep 2020 | |
Non-Hodgkin Lymphoma | Phase 1 | FI | 07 Sep 2020 | |
Non-Hodgkin Lymphoma | Phase 1 | DE | 07 Sep 2020 |
NCT04240704 (AACR2024) Manual | Phase 1 | 25 | jngyzqpkgh(pfvqlbxrpp) = hpkjxweqjr qsxlgrijlj (dtgamgtrhw ) View more | Positive | 05 Apr 2024 |